Breaking News Instant updates and real-time market news.

OCUL

Ocular Therapeutix

$4.02

-0.13 (-3.13%)

16:02
01/10/19
01/10
16:02
01/10/19
16:02

Ocular Therapeutix submits sNDA to FDA for Dextenza

Ocular Therapeutix announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for DEXTENZA. The sNDA filing seeks to expand the current indication for DEXTENZA to include the treatment of ocular inflammation following ophthalmic surgery. The company expects that the FDA review will be completed in the second half of 2019. DEXTENZA is the first FDA-approved intracanalicular insert delivering dexamethasone to treat post-surgical ocular pain for up to 30 days with a single administration. DEXTENZA received FDA approval in November 2018 for the treatment of ocular pain following ophthalmic surgery. DEXTENZA is a resorbable, preservative-free ophthalmic insert that is placed in the lower lacrimal punctum and into the canaliculus of the eye.

OCUL Ocular Therapeutix
$4.02

-0.13 (-3.13%)

12/03/18
CANT
12/03/18
NO CHANGE
Target $24
CANT
Overweight
Cantor Fitzgerald raises Ocular Therapeutix price target to $24 after approval
After Ocular Therapeutix announced that Dextenza has been approved by the FDA for the treatment of ocular pain following ophthalmic surgery approximately four weeks ahead of the December 28 PDUFA date, Cantor Fitzgerald analyst Elemer Piros raised his price target on Ocular shares to $24 from $22. He believes all manufacturing related issues have been addressed, adding that the upgraded manufacturing processes bode well for the company's entire platform. Piros maintains an Overweight rating on Ocular Therapeutix shares.
12/03/18
PIPR
12/03/18
NO CHANGE
Target $14
PIPR
Overweight
Piper calls Dextenza approval 'transformational' for Ocular Therapeutix
Piper Jaffray analyst Joseph Catanzaro views the FDA approval of Dextenza for the treatment of ocular pain following ophthalmic surgery as "transformational" for Ocular Therapeutix. The news lifts a "significant overhang" on the stock that has persisted for the last couple of years and allows Ocular to realize the full potential of the entire hydrogel platform. Notably, the approval came with no post-approval commitments outside of doing a pediatric study, Catanzaro tells investors in a research note. The analyst says that while meaningful sales are not expected until pass-through reimbursement is established, he currently model Dextenza sales in the post-cataract setting growing to $250M-plus by 2025. He keeps an Overweight rating on Ocular Therapeutix with a $14 price target. The stock in morning trading is down 5%, or 36c, to $6.30.
12/04/18
HCWC
12/04/18
NO CHANGE
Target $12
HCWC
Buy
Ocular Therapeutix price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Ocular Therapeutix to $12 after the FDA approved Dextenza for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. The analyst believes the news should bolster confidence in the company among investors. The approval not only validates Ocular's hydrogel drug delivery platform, but endorses the incumbent management team's execution and accountability, Selvaraju tells investors in a research note. He reiterates a Buy rating on the name.
01/04/19
PIPR
01/04/19
NO CHANGE
Target $14
PIPR
Overweight
Piper sees 'significant share appreciation' potential for Ocular Therapeutix
Ocular Therapeutix expects top-line data from OTX-TP's first Phase III glaucoma study in the first half of 2019, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. The analyst believes investors have discounted this program based on mixed Phase I/II data that utilized different formulations and study designs. However, he thinks the Phase III design gives OTX-TP the best chance at demonstrating clinical efficacy in this setting. A successful outcome will be statistically significant IOP-reductions over placebo at all time points and importantly, at least a 5 mm Hg reduction in IOP from baseline at 6 of the 9 time points, Catanzaro contends, citing his review of literature and a survey of ophthalmologists. He believes such an outcome would represent "another successful application of the hydrogel platform and drive significant share appreciation." The analyst has an Overweight rating on Ocular Therapeutix with a $14 price target.

TODAY'S FREE FLY STORIES

PLWTY

Panalpina

$0.00

(0.00%)

08:44
01/21/19
01/21
08:44
01/21/19
08:44
Downgrade
Panalpina rating change  »

Panalpina downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFGSY

Eiffage

$0.00

(0.00%)

08:41
01/21/19
01/21
08:41
01/21/19
08:41
Upgrade
Eiffage rating change  »

Eiffage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVFCF

Television Francaise 1

$0.00

(0.00%)

08:40
01/21/19
01/21
08:40
01/21/19
08:40
Downgrade
Television Francaise 1 rating change  »

Television Francaise 1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVDY

Atresmedia

$0.00

(0.00%)

08:37
01/21/19
01/21
08:37
01/21/19
08:37
Upgrade
Atresmedia rating change  »

Atresmedia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDPAY

Tod's

$0.00

(0.00%)

08:36
01/21/19
01/21
08:36
01/21/19
08:36
Downgrade
Tod's rating change  »

Tod's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFRGY

Salvatore Ferragamo

$0.00

(0.00%)

08:35
01/21/19
01/21
08:35
01/21/19
08:35
Downgrade
Salvatore Ferragamo rating change  »

Salvatore Ferragamo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:35
01/21/19
01/21
08:35
01/21/19
08:35
General news
FX Action: USD-CAD has nudged back above 1.3300 »

FX Action: USD-CAD has…

PRDSY

Prada

$0.00

(0.00%)

08:34
01/21/19
01/21
08:34
01/21/19
08:34
Upgrade
Prada rating change  »

Prada upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANDY

Pandora A/S

$0.00

(0.00%)

08:33
01/21/19
01/21
08:33
01/21/19
08:33
Downgrade
Pandora A/S rating change  »

Pandora A/S downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLGGF

SolGold

$0.00

(0.00%)

08:32
01/21/19
01/21
08:32
01/21/19
08:32
Initiation
SolGold initiated  »

SolGold initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCFBY

Pacific Basin Shipping

$0.00

(0.00%)

08:30
01/21/19
01/21
08:30
01/21/19
08:30
Upgrade
Pacific Basin Shipping rating change  »

Pacific Basin Shipping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:30
01/21/19
01/21
08:30
01/21/19
08:30
General news
Oil Action: Front-month WTI futures are near flat »

Oil Action: Front-month…

WFAFY

Wesfarmers

$0.00

(0.00%)

08:27
01/21/19
01/21
08:27
01/21/19
08:27
Downgrade
Wesfarmers rating change  »

Wesfarmers downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTOKY

Rentokil

$0.00

(0.00%)

08:26
01/21/19
01/21
08:26
01/21/19
08:26
Downgrade
Rentokil rating change  »

Rentokil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNTGY

Brenntag

$0.00

(0.00%)

08:25
01/21/19
01/21
08:25
01/21/19
08:25
Upgrade
Brenntag rating change  »

Brenntag upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:25
01/21/19
01/21
08:25
01/21/19
08:25
General news
Oil Action: Front-month WTI futures are near flat »

Oil Action: Front-month…

LOIMF

Loomis AB

$0.00

(0.00%)

08:24
01/21/19
01/21
08:24
01/21/19
08:24
Downgrade
Loomis AB rating change  »

Loomis AB downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank; also use SFTBF

$0.00

(0.00%)

08:21
01/21/19
01/21
08:21
01/21/19
08:21
Initiation
SoftBank; also use SFTBF initiated  »

SoftBank initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:00
01/21/19
01/21
07:00
01/21/19
07:00
General news
FX Update: There hasn't been a strong theme »

FX Update: There…

CYDY

CytoDyn

$0.00

(0.00%)

04:55
01/21/19
01/21
04:55
01/21/19
04:55
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

03:45
01/21/19
01/21
03:45
01/21/19
03:45
General news
FX Action: USD-CAD has settled back in the upper 1.3200s »

FX Action: USD-CAD has…

03:05
01/21/19
01/21
03:05
01/21/19
03:05
General news
FX Update: The Dollar majors have been trading with little directional bias »

FX Update: The Dollar…

MET

MetLife

$45.32

0.28 (0.62%)

19:55
01/20/19
01/20
19:55
01/20/19
19:55
Hot Stocks
MetLife announces Richard Nunn as new CEO for Australia »

MetLife announced Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 18

    Jun

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

, TSLA

Tesla

$302.26

-45.18 (-13.00%)

19:27
01/20/19
01/20
19:27
01/20/19
19:27
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

TSLA

Tesla

$302.26

-45.18 (-13.00%)

NFLX

Netflix

$339.20

-14.02 (-3.97%)

EA

Electronic Arts

$92.50

3.19 (3.57%)

ATVI

Activision Blizzard

$48.64

1.26 (2.66%)

CMCSA

Comcast

$36.21

0.32 (0.89%)

CMCSK

Comcast

$0.00

(0.00%)

COST

Costco

$213.59

2.15 (1.02%)

ILMN

Illumina

$312.66

2.53 (0.82%)

TMO

Thermo Fisher

$240.72

2.55 (1.07%)

DHR

Danaher

$107.43

1.88 (1.78%)

A

Agilent

$71.93

1.16 (1.64%)

TECH

Bio-Techne

$163.24

1.16 (0.72%)

NEM

Newmont Mining

$31.77

0.15 (0.47%)

GOLD

Barrick Gold

$11.78

-0.11 (-0.93%)

KRC

Kilroy Realty

$68.23

0.21 (0.31%)

VNO

Vornado

$66.40

1.04 (1.59%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 28

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 05

    Feb

  • 05

    Feb

  • 05

    Feb

  • 12

    Feb

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 03

    Mar

NTDOY

Nintendo

$0.00

(0.00%)

17:55
01/20/19
01/20
17:55
01/20/19
17:55
Periodicals
Nintendo investors starting to feel optimistic again, Bloomberg says »

Nintendo investors,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.